ERBB2 and breast cancer: Regarding the phase II trials, six studies focusing on neratinib’s efficiency, either in monotherapy or associated with paclitaxel or trastuzumab, in patients with advanced or metastatic HER2+ BC (FIGO IIIB, IIIC or IV), retained our attention.